Ultragenyx Pharmaceutical (RARE) EBIT Margin (2016 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly EBIT Margin of 124.26% for Q1 2026, down 2139.0% year-over-year from 6.09% in Q1 2025, and down 127.37% quarter-over-quarter from 54.65% in Q4 2025.
Ultragenyx Pharmaceutical (RARE) EBIT Margin (2016 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported EBIT Margin for 11 consecutive years, with 124.26% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT Margin fell 2139.0% year-over-year to 124.26%; the TTM figure through Mar 2026 stood at 83.78% (up 326.0% YoY), while the FY2025 annual figure was 79.49%, up 1622.0% from the prior year.
- EBIT Margin slipped to 124.26% in Q1 2026 per RARE's latest filing, from 54.65% in the prior quarter.
- Across five years, EBIT Margin topped out at 54.65% in Q4 2025 and bottomed at 248.14% in Q3 2022.
- Historically, EBIT Margin has averaged 123.86% across 5 years, with a median of 124.26% in 2026.
- Annual changes were most pronounced in 2022 — EBIT Margin plunged 13812 bps — and 2023, when it jumped 10016 bps.
- Ultragenyx Pharmaceutical's EBIT Margin stood at 140.91% in 2022, then jumped by 32 bps to 95.83% in 2023, then rose by 22 bps to 74.28% in 2024, then advanced by 26 bps to 54.65% in 2025, then tumbled by 127 bps to 124.26% in 2026.
- Business Quant data shows RARE's EBIT Margin at 124.26% in Q1 2026, 54.65% in Q4 2025, and 106.85% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn | -35.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -35.05% |
| Mar 31, 2026 | -124.26% |
| Dec 31, 2025 | -54.65% |
| Sep 30, 2025 | -106.85% |
| Jun 30, 2025 | -64.80% |
| Mar 31, 2025 | -102.88% |
| Dec 31, 2024 | -74.28% |
| Sep 30, 2024 | -94.62% |
| Jun 30, 2024 | -79.14% |
| Mar 31, 2024 | -151.93% |
| Dec 31, 2023 | -95.83% |
| Sep 30, 2023 | -147.98% |
| Jun 30, 2023 | -136.61% |
| Mar 31, 2023 | -153.34% |
| Dec 31, 2022 | -140.91% |
| Sep 30, 2022 | -248.14% |
| Jun 30, 2022 | -158.48% |
| Mar 31, 2022 | -170.93% |
| Dec 31, 2021 | -122.99% |
| Sep 30, 2021 | -110.02% |